{"id":37930,"date":"2025-07-25T12:44:33","date_gmt":"2025-07-25T04:44:33","guid":{"rendered":"https:\/\/flcube.com\/?p=37930"},"modified":"2025-07-25T12:44:34","modified_gmt":"2025-07-25T04:44:34","slug":"genfleet-therapeutics-announces-fast-track-designation-for-gfh375-vs-7375-in-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37930","title":{"rendered":"GenFleet Therapeutics Announces Fast Track Designation for GFH375\/VS-7375 in Pancreatic Cancer"},"content":{"rendered":"\n

China-based GenFleet Therapeutics announced on July 25, 2025, that its oral KRAS G12D inhibitor, GFH375\/VS-7375, has been granted Fast Track designation by the U.S. FDA. This designation applies to the first-line and later-line treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) harboring KRAS G12D mutations. GFH375 received clinical approval in China in June 2024 and is currently in Phase II development there. The Phase I\/IIa study of GFH375\/VS-7375 in the U.S. was initiated by GenFleet’s partner, Verastem Oncology (NASDAQ: VSTM<\/a>), earlier this year.<\/p>\n\n\n\n

Drug Mechanism and Clinical Progress<\/strong>
GFH375 is a highly potent, highly selective, non-covalent small molecule inhibitor targeting the KRAS G12D mutation. It inhibits tumor cell proliferation by blocking the sustained activation of KRAS and its downstream pathways. Phase I data presented at ASCO 2024 demonstrated an Overall Response Rate (ORR) of 52% and a Disease Control Rate (DCR) of 100% in PDAC patients. In NSCLC patients, the ORR was 42% and the DCR was 83%, indicating promising preliminary efficacy and oral bioavailability.<\/p>\n\n\n\n

Collaboration with Verastem Oncology<\/strong>
In August 2023, GenFleet Therapeutics entered into a licensing and early-stage co-development agreement with Verastem for three products developed by GenFleet. In January 2025, Verastem exercised its option for GFH375\/VS-7375, securing the development and commercialization rights for GFH375 outside of Greater China. This strategic partnership underscores the potential of GFH375 and accelerates its global development.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based GenFleet Therapeutics announced on July 25, 2025, that its oral KRAS G12D inhibitor, GFH375\/VS-7375,…<\/p>\n","protected":false},"author":1,"featured_media":37931,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,1682,2305,2304],"class_list":["post-37930","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-genfleet-therapeutics","tag-nasdaq-vstm","tag-verastem-oncology"],"yoast_head":"\nGenFleet Therapeutics Announces Fast Track Designation for GFH375\/VS-7375 in Pancreatic Cancer - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based GenFleet Therapeutics announced on July 25, 2025, that its oral KRAS G12D inhibitor, GFH375\/VS-7375, has been granted Fast Track designation by the U.S. FDA. This designation applies to the first-line and later-line treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) harboring KRAS G12D mutations. GFH375 received clinical approval in China in June 2024 and is currently in Phase II development there. The Phase I\/IIa study of GFH375\/VS-7375 in the U.S. was initiated by GenFleet's partner, Verastem Oncology (NASDAQ: VSTM), earlier this year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37930\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenFleet Therapeutics Announces Fast Track Designation for GFH375\/VS-7375 in Pancreatic Cancer\" \/>\n<meta property=\"og:description\" content=\"China-based GenFleet Therapeutics announced on July 25, 2025, that its oral KRAS G12D inhibitor, GFH375\/VS-7375, has been granted Fast Track designation by the U.S. FDA. This designation applies to the first-line and later-line treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) harboring KRAS G12D mutations. GFH375 received clinical approval in China in June 2024 and is currently in Phase II development there. The Phase I\/IIa study of GFH375\/VS-7375 in the U.S. was initiated by GenFleet's partner, Verastem Oncology (NASDAQ: VSTM), earlier this year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37930\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-25T04:44:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-25T04:44:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2505.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37930#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37930\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GenFleet Therapeutics Announces Fast Track Designation for GFH375\\\/VS-7375 in Pancreatic Cancer\",\"datePublished\":\"2025-07-25T04:44:33+00:00\",\"dateModified\":\"2025-07-25T04:44:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37930\"},\"wordCount\":244,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37930#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2505.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"GenFleet Therapeutics\",\"NASDAQ: VSTM\",\"Verastem Oncology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37930#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37930\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37930\",\"name\":\"GenFleet Therapeutics Announces Fast Track Designation for GFH375\\\/VS-7375 in Pancreatic Cancer - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37930#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37930#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2505.webp\",\"datePublished\":\"2025-07-25T04:44:33+00:00\",\"dateModified\":\"2025-07-25T04:44:34+00:00\",\"description\":\"China-based GenFleet Therapeutics announced on July 25, 2025, that its oral KRAS G12D inhibitor, GFH375\\\/VS-7375, has been granted Fast Track designation by the U.S. FDA. This designation applies to the first-line and later-line treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) harboring KRAS G12D mutations. GFH375 received clinical approval in China in June 2024 and is currently in Phase II development there. The Phase I\\\/IIa study of GFH375\\\/VS-7375 in the U.S. was initiated by GenFleet's partner, Verastem Oncology (NASDAQ: VSTM), earlier this year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37930#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37930\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37930#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2505.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2505.webp\",\"width\":1080,\"height\":608,\"caption\":\"GenFleet Therapeutics Announces Fast Track Designation for GFH375\\\/VS-7375 in Pancreatic Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37930#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenFleet Therapeutics Announces Fast Track Designation for GFH375\\\/VS-7375 in Pancreatic Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GenFleet Therapeutics Announces Fast Track Designation for GFH375\/VS-7375 in Pancreatic Cancer - Insight, China's Pharmaceutical Industry","description":"China-based GenFleet Therapeutics announced on July 25, 2025, that its oral KRAS G12D inhibitor, GFH375\/VS-7375, has been granted Fast Track designation by the U.S. FDA. This designation applies to the first-line and later-line treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) harboring KRAS G12D mutations. GFH375 received clinical approval in China in June 2024 and is currently in Phase II development there. The Phase I\/IIa study of GFH375\/VS-7375 in the U.S. was initiated by GenFleet's partner, Verastem Oncology (NASDAQ: VSTM), earlier this year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37930","og_locale":"en_US","og_type":"article","og_title":"GenFleet Therapeutics Announces Fast Track Designation for GFH375\/VS-7375 in Pancreatic Cancer","og_description":"China-based GenFleet Therapeutics announced on July 25, 2025, that its oral KRAS G12D inhibitor, GFH375\/VS-7375, has been granted Fast Track designation by the U.S. FDA. This designation applies to the first-line and later-line treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) harboring KRAS G12D mutations. GFH375 received clinical approval in China in June 2024 and is currently in Phase II development there. The Phase I\/IIa study of GFH375\/VS-7375 in the U.S. was initiated by GenFleet's partner, Verastem Oncology (NASDAQ: VSTM), earlier this year.","og_url":"https:\/\/flcube.com\/?p=37930","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-25T04:44:33+00:00","article_modified_time":"2025-07-25T04:44:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2505.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37930#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37930"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GenFleet Therapeutics Announces Fast Track Designation for GFH375\/VS-7375 in Pancreatic Cancer","datePublished":"2025-07-25T04:44:33+00:00","dateModified":"2025-07-25T04:44:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37930"},"wordCount":244,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37930#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2505.webp","keywords":["Cancer","Clinical trial approval \/ initiation","GenFleet Therapeutics","NASDAQ: VSTM","Verastem Oncology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37930#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37930","url":"https:\/\/flcube.com\/?p=37930","name":"GenFleet Therapeutics Announces Fast Track Designation for GFH375\/VS-7375 in Pancreatic Cancer - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37930#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37930#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2505.webp","datePublished":"2025-07-25T04:44:33+00:00","dateModified":"2025-07-25T04:44:34+00:00","description":"China-based GenFleet Therapeutics announced on July 25, 2025, that its oral KRAS G12D inhibitor, GFH375\/VS-7375, has been granted Fast Track designation by the U.S. FDA. This designation applies to the first-line and later-line treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) harboring KRAS G12D mutations. GFH375 received clinical approval in China in June 2024 and is currently in Phase II development there. The Phase I\/IIa study of GFH375\/VS-7375 in the U.S. was initiated by GenFleet's partner, Verastem Oncology (NASDAQ: VSTM), earlier this year.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37930#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37930"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37930#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2505.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2505.webp","width":1080,"height":608,"caption":"GenFleet Therapeutics Announces Fast Track Designation for GFH375\/VS-7375 in Pancreatic Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37930#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GenFleet Therapeutics Announces Fast Track Designation for GFH375\/VS-7375 in Pancreatic Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2505.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37930","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37930"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37930\/revisions"}],"predecessor-version":[{"id":37932,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37930\/revisions\/37932"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37931"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37930"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37930"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37930"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}